GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (FRA:UDD) » Definitions » PB Ratio

Prescient Therapeutics (FRA:UDD) PB Ratio : 5.00 (As of May. 03, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Prescient Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-03), Prescient Therapeutics's share price is €0.11. Prescient Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was €0.02. Hence, Prescient Therapeutics's PB Ratio of today is 5.00.

The historical rank and industry rank for Prescient Therapeutics's PB Ratio or its related term are showing as below:

FRA:UDD' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 9.06
Current: 1.86

During the past 13 years, Prescient Therapeutics's highest PB Ratio was 9.06. The lowest was 0.00. And the median was 0.00.

FRA:UDD's PB Ratio is ranked better than
64.18% of 1312 companies
in the Biotechnology industry
Industry Median: 2.48 vs FRA:UDD: 1.86

During the past 12 months, Prescient Therapeutics's average Book Value Per Share Growth Rate was -17.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 4.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -6.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Prescient Therapeutics was 181.60% per year. The lowest was -74.10% per year. And the median was -18.60% per year.

Back to Basics: PB Ratio


Prescient Therapeutics PB Ratio Historical Data

The historical data trend for Prescient Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics PB Ratio Chart

Prescient Therapeutics Annual Data
Trend Jun13 Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.91 1.62 - - -

Prescient Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Prescient Therapeutics's PB Ratio

For the Biotechnology subindustry, Prescient Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prescient Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's PB Ratio falls into.



Prescient Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Prescient Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.11/0.022
=5.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Prescient Therapeutics  (FRA:UDD) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Prescient Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Prescient Therapeutics (FRA:UDD) Business Description

Traded in Other Exchanges
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (FRA:UDD) Headlines

No Headlines